| Not Yet Recruiting | Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia NCT07376889 | Intermountain Health Care, Inc. | Phase 4 |
| Recruiting | Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia NCT06650501 | McGill University Health Centre/Research Institute of the McGill University Health Centre | Phase 4 |
| Enrolling By Invitation | Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes? NCT07148960 | West Virginia University | Phase 4 |
| Recruiting | Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia NCT06637332 | Todd C. Lee MD MPH FIDSA | Phase 4 |
| Active Not Recruiting | Adjunctive Fosfomycin for Treatment of Staphylococcus Aureus Bacteraemia NCT06695832 | Hospital Universitari de Bellvitge | — |
| Recruiting | Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia NCT06336824 | Clinical Research Centre, Malaysia | Phase 3 |
| Recruiting | Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia NCT04886284 | Todd C. Lee MD MPH FIDSA | Phase 2 |
| Completed | Staphylococcus Aureus Bacteraemia (SAB)-Support-Study NCT06249451 | University Medicine Greifswald | N/A |
| Recruiting | Evaluating Simplified Layered Consent for Clinical Trials NCT06168474 | Sunnybrook Health Sciences Centre | N/A |
| Unknown | Evaluation of the Usefulness of Echocardiography in Patients With Staphylococcus Aureus Bacteremia (ET-AUREUS NCT05862025 | Puerta de Hierro University Hospital | N/A |
| Not Yet Recruiting | 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia NCT05361135 | University College, London | N/A |
| Recruiting | Identification and Validation of Clinical Phenotypes in Staphylococcus Aureus Bacteremia and Their Association NCT06574399 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | — |
| Completed | Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacterem NCT05184764 | Armata Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Recruiting | Staphylococcus Aureus Network Adaptive Platform Trial NCT05137119 | University of Melbourne | Phase 4 |
| Terminated | Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase NCT04160468 | ContraFect | Phase 3 |
| Withdrawn | Oritavancin for Staphylococcus Aureus Infections in Opioid Users NCT03761953 | University of Pennsylvania | Phase 4 |
| Completed | Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia NCT03138733 | Basilea Pharmaceutica | Phase 3 |
| Unknown | Seven Versus Fourteen Days of Treatment in Uncomplicated Staphylococcus Aureus Bacteremia NCT03514446 | Thomas Benfield | Phase 4 |
| Completed | Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment NCT03163446 | ContraFect | Phase 2 |
| Terminated | Phase IIa Clinical Study of N-Rephasin® SAL200 NCT03089697 | Intron Biotechnology, Inc. | Phase 2 |
| Completed | The Benefit of FDG PET CT in the Treatment Algorithm of Staphylococcus Aureus Bacteremia NCT02476487 | Rambam Health Care Campus | N/A |
| Completed | Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects. NCT02357966 | XBiotech, Inc. | Phase 1 / Phase 2 |
| Completed | Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent NCT01701219 | Forest Laboratories | Phase 4 |
| Unknown | Staphylococcus Aureus Bacteraemia in Adults NCT02098850 | University of Cologne | — |
| Completed | Staphylococcus Aureus Bacteremia: Impact of an Intervention Program in Improving the Clinical Management and R NCT01971762 | Fundación Pública Andaluza Progreso y Salud | — |
| Unknown | Early Infectious Disease Consultations in Staphylococcus Aureus Bacteremia NCT00622882 | National University Hospital, Singapore | N/A |
| Completed | Bloodstream Infections in Patients With Rheumatoid Arthritis NCT03908086 | Sabine Dieperink | — |
| Completed | Clinical Trial Comparing Safety and Pharmacokinetics of Standard Antibiotic Therapy, Plus Aurexis® or Placebo, NCT00198302 | Bristol-Myers Squibb | Phase 2 |